Subscribe To
In8bio to present new positive data from phase 1 trial of inb-100 at 2023 american society of hematology (ash) annual meeting
New data on the completed dose-escalation of this Phase 1 trial highlights promising efficacy of INB-10...
November 2, 2023, 1:17 pm
Cardiol therapeutics reaches new milestone in phase ii study for recurrent pericarditis
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced it has successfully enrolled over 50% of the targeted number of patients for its Phase II open-...
November 1, 2023, 8:41 am
Cassava sciences: my bullish take on biomarkers and ctad data
Cassava Sciences' stock is highly disputed due to conflicting opinions on the science behind its drug candidate, but outside research supports its app...
October 30, 2023, 3:30 am
Why is apollomics (aplm) stock up 113% today?
Apollomics (NASDAQ: APLM ) stock is rising higher on Friday as the shares bounce back on recent study results. Those study results cover the “...
October 27, 2023, 8:03 am
Apollomics announces report of activity of vebreltinib in glioblastoma multiforme (gbm) with ptprz-met fusion
FOSTER CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) — Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced a report by the Veneto Ins...
October 26, 2023, 12:50 pm
Ecb to finally pause, eur/usd looking soft
Today, ECB is broadly anticipated to maintain its main refinancing rate at 4.50% and the deposit rate at 4.00%. Having increased rates consistently du...
October 26, 2023, 2:40 am
New data from biogen’s investigational antisense oligonucleotide (aso) targeting tau shows promise for potential new generation of treatments in early alzheimer’s disease
In the Phase 1b study, favorable trends were reported for the high-dose groups on multiple measures of cognition and function. First study of a tau ta...
October 25, 2023, 2:51 pm
From bill gates to the pope, talk of carbon capture and its efficacy is dividing society
The sector's potential was a hot topic at the recent ADIPEC oil and gas conference....
October 25, 2023, 12:57 am
Ambrx: next-generation antibody-drug conjugates, buying the dip after esmo data
Ambrx Biopharma Inc. common stock experienced an irrational selloff following the Phase 1/2 ESMO data release for its ADC candidate ARX517, presenting...
October 24, 2023, 11:23 am
Dupixent® (dupilumab) phase 3 results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (eoe)
Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher...
October 22, 2023, 6:59 pm
Potential of arvinas’ protac® ar degraders reinforced by 11.1 months rpfs with bavdegalutamide and updated positive interim data from second generation arv-766 in mcrpc
– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic progress...
October 22, 2023, 11:00 am
Rosuvastatin, atorvastatin have comparable efficacy for cad
Rosuvastatin and atorvastatin have comparable efficacy for a composite outcome in adults with coronary ...
October 19, 2023, 7:14 pm
Cvs health to remove cold medicine with phenylephrine from shelves - wsj
CVS Health is pulling some of the most common decongestants with phenylephrine from its shelves and will no longer sell them, after advisers to U.S. h...
October 19, 2023, 3:20 pm
Maia biotechnology to present preliminary safety and efficacy data from thio-101 phase 2 clinical trial at european society for medical oncology congress 2023
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present Preliminary Safety and efficacy Data from THIO-...
October 19, 2023, 8:35 am
60 degrees pharma to present review of safety, efficacy data of 8-aminoquinolines for malaria and babesiosis treatment at ilads annual scientific meeting in boston
60 Degrees Pharma Presents Review of Safety, efficacy Data of 8-Aminoquinolines for Malaria and Babesio...
October 19, 2023, 8:31 am
Cytomx therapeutics presents preclinical profile of epcam-directed antibody drug conjugate cx-2051 at 2023 world adc conference
– CX-2051 is tailored for treatment of EpCAM-expressing cancers by matching target expression and tumor sensitivity with a topoisomerase-1 inhibitor...
October 18, 2023, 8:30 pm
Coherus announces toripalimab data at 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics
— Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical ...
October 14, 2023, 4:30 pm
Relmada and rel-1017: intriguing underlying efficacy in mdd ahead of eventful 2024
Phase 3 trial failures were due to abnormally high placebo responses driven by poor trial design, enrollment, and oversight. REL-1017's underlying
October 13, 2023, 7:50 pm
Processa pharmaceuticals to present at the thinkequity conference
HANOVER, MD, Oct. 13, 2023 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage ...
October 13, 2023, 5:08 pm
Processa pharmaceuticals to present at the thinkequity conference
HANOVER, MD, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage p...
October 13, 2023, 1:08 pm